Evaluation of paromomycin sulphate permeation using ex vivo human skin model

Pharm Dev Technol. 2019 Mar;24(3):390-393. doi: 10.1080/10837450.2018.1485697. Epub 2018 Jul 13.

Abstract

Ex vivo evaluation of drug release and skin permeation from topical formulations of antileishmanial drug paromomycin sulphate was carried out using intact full thickness human skin. Potency-based microbiological assay was used for the analysis of paromomycin concentrations. A total percentage drug recovery of 86 ± 26% was obtained. Incubation periods of 1 and 3 h resulted in percentage drug permeation into deep skin layers ranging from 1.3 ± 0.04% to 5.3 ± 2.0% with paraffin-based ointment and from 1.6 ± 0.8% to 3.9 ± 1% with microemulsion-based emulgel. Although a small percentage, this is still significantly higher than those previously reported using animal skin models.

Keywords: Paromomycin permeation; cutaneous leishmaniasis; human skin; potency-based microbiological assay; topical emulgel.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Antiprotozoal Agents / administration & dosage*
  • Antiprotozoal Agents / pharmacokinetics
  • Drug Liberation
  • Emulsions
  • Female
  • Humans
  • Ointments
  • Paromomycin / administration & dosage*
  • Paromomycin / pharmacokinetics
  • Permeability
  • Skin / metabolism*
  • Skin Absorption*
  • Species Specificity
  • Time Factors

Substances

  • Antiprotozoal Agents
  • Emulsions
  • Ointments
  • Paromomycin